The International Osteoporosis Foundation (IOF)
New Capture the Fracture® partnership aims for 25% reduction in the incidence of hip and vertebral fractures due to osteoporosis by 2025
mehr
Ergebnis der Suchanfrage nach Nü
Inhalte
- Sprache:
-
Medien:
Alle
- Zeitraum:
- Zeitraum:Gesamt
814 Treffer
Switching to Ozempic® from another GLP-1 RA significantly reduced blood sugar and weight in people with type 2 diabetes in routine clinical practice
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only, excl US. For journalistic assessment and preparation before publication. - A separate real-world study showed that people with type 2 diabetes on two oral antidiabetic drugs who intensified with a glucagon-like peptide-1 ...
mehrUCB's General Meeting of Shareholders
Brussels (ots/PRNewswire) - - Update on attendance and voting instructions relating to UCB's General Meeting of 30 April 2020 - Implementation of Royal Decree n°4 of 9 April 2020 on various provisions regarding the legislation on co-ownership and companies and associations, in the framework of the fight against the Covid-19 pandemic - No physical presence at General Meeting allowed and votes can only be submitted by ...
mehrZentiva and IKEA Joining Forces to Fight the COVID-19 Pandemic
Prague (ots/PRNewswire) - Zentiva Group, a.s. announces the agreement with IKEA to cooperate during the COVID-19 crisis. As part of this collaboration, Zentiva Romania will temporarily employ 18 employees from IKEA Romania for 3 months to sustain the production of medicines supply following the increasing demand. " At Zentiva we are doing everything in our power to help authorities fight COVID-19. Zentiva is working on ...
mehrUCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn targeting ...
mehrSaxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...
mehr
EANS-News: ams AG / Notice to holders of the EUR 600,000,000 Convertible Bonds without interest due 2025 Convertible into Bearer Shares With No Par Value of ams AG (the ?Issuer?) (ISIN: DE000A19W2L5)
issuer: ams AG Tobelbader Strasse 30 A-8141 Premstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com ISIN: AT0000A18XM4 indexes: stockmarkets: SIX Swiss Exchange language: ...
mehrEANS-News: ams AG / Notice to holders of the USD 350,000,000 0.875 per cent. Convertible Bonds due 2022 Convertible into Bearer Shares With No Par Value of ams AG (the ?Issuer?) (ISIN: DE000A19PVM4)
issuer: ams AG Tobelbader Strasse 30 A-8141 Premstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com ISIN: AT0000A18XM4 indexes: stockmarkets: SIX Swiss Exchange language: ...
mehrNew Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease
Amsterdam (ots/PRNewswire) - - Ferric maltol (FM) was associated with substantially lower use of healthcare resources than IV ferric carboxymaltose (FCM) - IV FCMwas linked to greater productivity loss and disruption to patients' work and family life due to the need for clinic-based IV administration - 50% of ...
mehrSwissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Ein DokumentmehrCrisis Management Professionals Invited to DRIVER+ Advanced Crisis Management Conference in Brussels From February 19-20, 2020
London (ots/PRNewswire) - - Crisis management practitioners, researchers, policymakers and solutions providers with an interest in innovation are invited to attend the international emergency management conference of the EU-funded DRIVER+ project at the BluePoint conference centre in Brussels on February 19-20, 2020 ...
mehrEANS-News: ams AG / Convocation of the Extraordinary General Meeting
issuer: ams AG Tobelbader Strasse 30 A-8141 Premstaetten phone: +43 3136 500-0 FAX: +43 3136 500-931211 mail: investor@ams.com WWW: www.ams.com ISIN: AT0000A18XM4 indexes: stockmarkets: SIX Swiss Exchange language: English ...
mehr
COMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers
London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...
mehrJennewein Biotechnologie sues Glycom for patent infringement in Denmark
Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the ...
mehr- Oral ferric maltol may offer an alternative treatment option to IV iron even in patients who have failed or not tolerated current oral iron treatments[1]
Amsterdam (ots/PRNewswire) - Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics, presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy, was found to be non-inferior to ...
mehrUCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3 - Will enrich UCB's pipeline; zilucoplan is a novel, ...
mehrA pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
mehrNovo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration ...
mehr
Abstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers
Not intended for US, Canada and UK-based media Darmstadt, Germany, and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
mehrEASL European Association for the study of the Liver
2Obesity epidemic results in Non-Alcoholic Fatty Liver Disease (NAFLD) becoming the most common cause of liver disease in Europe
mehrEthicon Launches New Powered Circular Stapler With Dual Technologies to Reduce Anastomotic Complications in Colorectal, Gastric, and Thoracic Surgery
Innovative technology helps address critical challenge of anastomotic leaks which can occur in up to 8.6% of colorectal surgeries1,11% in oesophagectomies2 and 4% in gastrectomies3 Vienna (ots/PRNewswire) - Ethicon*, part of the Johnson & Johnson Medical Devices Companies**, today announced the launch of the ...
mehrExperts Consider Osteoporosis to Be a Silent Epidemic Which Is Neglected and Under Addressed, According to New Survey Released Today
- Osteoporosis is estimated to affect 200 million people worldwide1 and results in a fracture every 3 seconds2 yet a new survey reveals bone specialists in Europe think its impact is not fully recognised3 - Specialists (82%) believe osteoporosis is a silent epidemic, yet only 24% believe their healthcare system is ...
mehrHovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
mehrETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF Patients
- Global and European real-world outcome analyses in non-selected atrial fibrillation (AF) patients on edoxaban, including those who are elderly with comorbidities, were reported at ESC Congress 2019 - At present, the Global ETNA-AF programme is the largest and most comprehensive repository of routine clinical ...
mehr
Leadership Changes in Mindtree Following Change of Control
Warren, New Jersey and Bangalore, India (ots/PRNewswire) - Mindtree, a global technology services and Digital transformation company, announced that Krishnakumar Natarajan, Executive Chairman, N S Parthasarathy, Executive Vice Chairman and Chief Operating Officer and Rostow Ravanan, CEO and Managing Director have submitted their resignations as members of the Board of Directors of Mindtree Ltd and as employees of the ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Sediments in Lake Geneva reflect the 2008 financial crisis
Bern (ots) - An analysis of sediment transport in the Rhône Valley yields surprising results: melting glaciers overcompensated for the effect of the increased number of hydropower plants. A reduction in construction activities due to the 2008 financial crisis could also be seen in the data. This comprehensive study, the first of its kind in Europe, brings important new knowledge, in particular for flood prevention. Water ...
mehrMerck to Showcase New Data Across MS Portfolio at EAN 2019
Not intended for UK or U.S. based media Darmstadt, Germany (ots/PRNewswire) - - Company to present 16 abstracts on MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib at the 5th Congress of the European Academy of Neurology - Presentations include new data on the long-term efficacy and safety of MAVENCLAD®, new safety data for Rebif® and the 48-week analysis from the Phase 2 ...
mehrEANS-News: Rottami Metalli Italia S.p.A. / - ATTACHMENT
http://resources.euroadhoc.com/documents/10250667/5/10323457/1/comunicato_2019_06_20.pdf issuer: Rottami Metalli Italia S.p.A. Via G. Galilei 19 I-37014 Castelnuovo del Garda (VR) phone: ++39(0)45/7570877 FAX: ++39(0)45/6450022 mail: Franco.Sesso@rmispa.com WWW: https://www.rmispa.com/it ISIN: IT0005329328 indexes: stockmarkets: Wien language: English ...
mehrMerck to Present New Data on Mavenclad®, Rebif® and the Investigational Therapy Evobrutinib at the AAN Annual Meeting 2019
Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that data from ...
mehrEANS-News: Rottami Metalli Italia S.p.A. /
issuer: Rottami Metalli Italia S.p.A. Via G. Galilei 19 I-37014 Castelnuovo del Garda (VR) phone: ++39(0)45/7570877 FAX: ++39(0)45/6450022 mail: Franco.Sesso@rmispa.com WWW: https://www.rmispa.com/it ISIN: IT0005329328 indexes: stockmarkets: Wien language: English ...
mehr
Vorherige12345678910Nächste